You are here

  • Home
  • Archive
  • Volume 19, Issue 2
  • Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Aspirin plus clopidogrel in acute minor ischaemic stroke or transient ischaemic attack is superior to aspirin alone for stroke risk reduction: CHANCE trial
  1. Philip B Gorelick,
  2. Muhammad U Farooq
  1. Mercy Health Hauenstein Neuroscience Center, Grand Rapids, Michigan, USA
  1. Correspondence to: Dr Philip B Gorelick, Mercy Health Hauenstein Neuroscience Center, Vascular Neurology and Stroke, 220 Cherry Street SE, Grand Rapids, MI 49503, USA; pgorelic{at}mercyhealth.com

https://doi.org/10.1136/eb-2013-101512

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19.OpenUrlCrossRefPubMedWeb of Science

    Context

    Combination therapy with aspirin added to clopidogrel has had a disappointing record in the prevention of recurrent stroke. The management of atherothrombosis with clopidogrel in high-risk patients (MATCH)1 and the secondary prevention of small subcortical strokes (SPS3)2 randomised controlled trials (RCTs) showed that combination therapy was not more effective than clopidogrel or aspirin alone, but was associated with two to three times the risk of major or life-threatening haemorrhage in one study, and major haemorrhages were increased by almost double in the other study. Fast assessment of stroke and transient ischemic attack (TIA) to prevent early recurrence (FASTER), a pilot RCT3 to …

    View Full Text

    Footnotes

    • Competing interests None.